A 70-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer - Episode 6
Dr. Morgans discusses unmet needs and importance of including multidisciplinary teams when treating patients with mCRPC.
Alicia Morgans, MD, MPH: Until we cure patients of prostate cancer, including metastatic CRPC [castration-resistant prostate cancer], there will always be an unmet need in this disease space and for these men. Combinations of therapies, including 177Lutetium or not, will hopefully get us over the goal line at some point and give us the opportunity to say—even for men with disease that we can’t cure—they’re cured. There are many exciting combination studies being done with radiopharmaceuticals, PARP inhibitors with AR [androgen receptor]–directed therapies, immunotherapies, and other things that we don’t know exist but are in early phase 1 or first-in-human trials and are moving into our field. It’s an incredibly exciting time in prostate cancer, and I look forward to seeing our opportunities for treatment grow; the sky is the limit. With a partnership between patients who want to engage in clinical trials and physicians who can open and run these safely and effectively for our patients, we can make quite a difference over time.
One piece of advice that I would offer is to continue to engage as multidisciplinary care teams that includes urologists and medical oncologists but now will increasingly also include nuclear medicine physicians and others who feel comfortable and are skilled to give our radiopharmaceuticals. We’re also recognizing that supportive care of bone health and protecting the cardiovascular health of our patients is critical. Engaging with our colleagues who can help support patients in these areas, and learning those skills on our own and incorporating them into our clinics, is critical in treating the whole patient.
Transcript edited for clarity.
A 70-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer
A 70-year-old man presents with nocturia and decreased appetite